Wordt geladen...
Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials
BACKGROUND: Fingolimod is a once-daily, orally administered therapy for relapsing forms of MS. It has been shown to reduce relapse rates significantly in all phase II and phase III clinical trials when compared with placebo and intramuscular interferon β-1a (IFNβ-1a IM). METHODS: This study compared...
Bewaard in:
| Gepubliceerd in: | Mult Scler Relat Disord |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4985567/ https://ncbi.nlm.nih.gov/pubmed/27456887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2016.05.015 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|